Charles River Laboratories International, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Charles River Laboratories International, Inc. announces a leadership transition with CEO James C. Foster's retirement, the appointment of Birgit Girshick as his successor, and proposals for a new long-term incentive plan and director elections at its 2026 Annual Meeting.
NYSE
Charles River Laboratories International, Inc. is set to hold its 2025 Annual Meeting of Shareholders on May 20, 2025, featuring proposals including director elections, executive compensation, auditor ratification, and a shareholder proposal concerning nonhuman primate imports.
NYSE
DEFA14A: Charles River Laboratories Urges Shareholders to Reject Proposal on Non-Human Primate Reporting
Charles River Laboratories files a supplement to its proxy statement, reiterating its opposition to a shareholder proposal requesting a report on non-human primates (NHPs) imported by the company, arguing that existing disclosures already meet and exceed the proposal's requests.
NYSE
Charles River Laboratories announces its 2024 Annual Meeting of Shareholders to be held on May 8, 2024, in Boston.